Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, has reported an increase in revenues and adjusted earnings for the second quarter of 2024.
Second-quarter revenue increased 5% from last year to $7.0 billion, aided by higher product sales in HIV, Liver Disease, and OncologyEarnings, on a per-share basis, were $1.29 in the second quarter, compared to $0.83 in the same period in 2023Adjusted earnings per share increased to $2.01 in the June quarter from $1.34 in the prior-year periodNet income attributable to Gilead advanced to $1.61 billion in Q2 from $1.05 billion in the year-ago quarterAs of June 30, 2024, the company had $2.8 billion of cash, cash equivalents, and marketable debt securities, vs. $8.4 billion a year earlierDuring the quarter, Gilead generated $1.3 billion in operating cash flow; it paid dividends of $972 million and repurchased $100 million of common stock
The post Earnings Summary: Gilead Sciences reports higher Q2 revenue and profit first appeared on AlphaStreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
